Atara Biotherapeutics (ATRA) EBIT Margin (2021 - 2026)
Atara Biotherapeutics (ATRA) posted EBIT Margin of 652.91% for Q1 2026, down 306.32% on a QoQ basis from 160.69% in Q4 2025, and down 69244.0% year-over-year from N/an in Q1 2025.
Atara Biotherapeutics (ATRA) EBIT Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics' EBIT Margin history runs 6 years deep, the most recent figure standing at 652.91% for Q1 2026.
- Quarterly EBIT Margin fell 69244.0% year-over-year to 652.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.27% (down 2056.0% YoY) and the FY2025 annual result came in at 29.69%, up 9440.0% from the prior year.
- EBIT Margin was 652.91% for Q1 2026 at Atara Biotherapeutics, down from 160.69% in the prior quarter.
- Across five years, EBIT Margin topped out at 1992.09% in Q4 2023 and bottomed at 43545.12% in Q2 2023.
- A 5-year average of 3802.16% and a median of 108.86% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin slumped 4348283 bps — and 2024, when it surged 4348147 bps.
- Atara Biotherapeutics' EBIT Margin stood at 4260.52% in 2022, then surged by 147 bps to 1992.09% in 2023, then tumbled by 102 bps to 37.26% in 2024, then sank by 331 bps to 160.69% in 2025, then slumped by 306 bps to 652.91% in 2026.
- Business Quant data shows ATRA's EBIT Margin at 652.91% in Q1 2026, 160.69% in Q4 2025, and 103.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | -652.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -652.91% |
| Dec 31, 2025 | -160.69% |
| Sep 30, 2025 | -103.50% |
| Jun 30, 2025 | 18.19% |
| Mar 31, 2025 | 39.53% |
| Dec 31, 2024 | -37.26% |
| Sep 30, 2024 | -54.14% |
| Jun 30, 2024 | -63.66% |
| Mar 31, 2024 | -114.22% |
| Dec 31, 2023 | 1,992.09% |
| Sep 30, 2023 | -3,446.14% |
| Jun 30, 2023 | -43,545.12% |
| Mar 31, 2023 | -8,486.20% |
| Dec 31, 2022 | -4,260.52% |
| Sep 30, 2022 | -1,897.78% |
| Jun 30, 2022 | -62.30% |
| Dec 31, 2021 | -1,237.45% |
| Sep 30, 2021 | -1,579.37% |
| Jun 30, 2021 | -2,170.59% |
| Mar 31, 2021 | -2,202.84% |